# Antengene Announces First Patient Dosed in Phase I ATTRACT Study Evaluating ATG-201 (CD19 × CD3 TCE) for B Cell-Mediated Autoimmune Diseases

- Source: PR Newswire M&A
- Published: 2026-11-06T00:30:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/antengene-announces-first-patient-dosed-in-phase-i-attract-study-evaluating-atg-201-cd19-O-cd3-tce-for-b-cell-mediated-autoimmune-diseases-302930435.html
- Canonical: https://groundlevelnews.com/story/antengene-announces-first-patient-dosed-in-phase-i-attract-study-evalu-615d64/

SHANGHAI and HONG KONG, Nov. 5, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._